Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early entrant to the field of machine learning for cardiology-focused clinical solutions. By leveraging large stores of deidentified data that span full patient journeys from physician notes to medications and imaging files, Anumana develops cardiac AI-based solutions that can glean pertinent disease information from electrocardiogram (ECG)waveforms. The company’s first FDA-cleared cardiac ECG-AI algorithm detects low ejection fraction (LEF), and two additional algorithms for pulmonary hypertension and cardiac amyloidosis are under review.
Anumana Makes Educated Inferences in Heart Failure
Related Articles
Anumana Receives First and Only FDA Clearance for ECG-AI Cardiac Amyloidosis Algorithm Using a Standard 12-Lead ECG
CAMBRIDGE, Mass., April 8, 2026—Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI® algorithm for cardiac amyloidosis (CA) – the…{post_date: F d, Y}
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to itsAI-enhanced, ECG-basedPulmonary Hypertension(PH) Early…{post_date: F d, Y}
Anumana Expands AI Platform from Diagnostic Solutions to the Full Continuum of Cardiovascular Care
New investment fuels growth of ECG-AI platform and development of perioperative AI capabilities{post_date: F d, Y}
How a New AI Algorithm Could Help in the Early Detection of Heart Disease
Xtalks: An AI algorithm developed by researchers at the Mayo Clinic through its newly formed health technology company Anumana Inc., can assess for low ejection fraction through routine electrocardiograms (ECG,…{post_date: F d, Y}